Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 7, 2010, Pages 1333-1341

  Kontis, Dimitrios ^a,b   Theochari, Eirini ^a   Kleisas, Spyridon ^a   Kalogerakou, Stamatina ^b   Andreopoulou, Angeliki ^a   Psaras, Rafael ^a   Makris, Yannis ^a,b   Karouzos, Charalambos ^a   Tsaltas, Eleftheria ^b  

^a Psychiatric Hospital of Attika Dafni   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

CANTAB; Cognition; Excessive dosage; Polypharmacy; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BRAIN FUNCTION; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOTOR CONTROL; PATTERN RECOGNITION; POLYPHARMACY; SCHIZOPHRENIA; SPATIAL MEMORY; TASK PERFORMANCE; WORKING MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYPHARMACY; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77956451696     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.07.029     Document Type: Article

References (79)

1. Addington D., Addington J., Maticka-Tyndale E., Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992, 6:201-208.
2. Akdede B.B., Anil Yaǧcioǧlu A.E., Alptekin K., Turgut T.I., Tümüklü M., Yazici M.K., et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry 2006, 67:1912-1919.
3. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, Washington DC. 4th ed.
4. Badcock J.C., Michiel P.T., Rock D. Spatial working memory and planning ability: contrasts between schizophrenia and bipolar I disorder. Cortex 2005, 41(6):753-763.
5. Blyler C.R., Gold J.M. Cognitive effects of typical antipsychotic treatment: Another look. Cognition in Schizophrenia, Impairments, Importance and Treatment Strategies 2000, 241-285. Oxford University Press, New York. T. Sharma, P. Harvey (Eds.).
6. Bonferroni C.E. Teoria statistica delle classi e calcolo delle probabilita. Pubbl Istit Sup Sci Econ Commerc Firenze 1936, 8:3-62.
7. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S., Leon A.C., et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial designs for neurocognitive drugs for schizophrenia. Schizophr Bull 2005, 31:5-21.
8. Carnahan R.M., Lund B.C., Perry P.J., Chrischilles E.A. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiat Scand 2006, 113:135-141.
9. Cassens G., Inglis A.K., Appelbaum P.S., Gutheil T.G. Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990, 16:477-499.
10. Centorrino F., Goren J.L., Hennen J., Salavtore P., Kelleher J.P. Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am J Psychiatry 2004, 161:700-706.
11. Chakos M.H., Glick I.D., Miller A.L., Hamner M.B., Miller D.D., Patel J.K., et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006, 57(8):1094-1101.
12. Chew M.L., Mulsant B.H., Pollock B.G., Lehman M.E., Greenspan A., Kirshner M.A., et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006, 88(1-3):63-72.
13. Chew M.L., Mulsant B.H., Pollock B.G., Lehman M.E., Greenspan A., Mahmoud R.A., et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008, 56(7):1333-1341.
14. Chouinard G., Margolese H.C. Manual for the Extrapyramidal Rating Scale (ESRS). Schizophr Res 2005, 76:247-265.
15. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res 2007, 89(1-3):91-100.
16. Davidson M., Galderisi S., Weiser M., Werbeloff N., Fleischhacker W.W., Keefe R.S., et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009, 166:675-682.
17. Davis J.M., Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004, 24:192-208.
18. Diaz F.J., De Leon J. Excessive antipsychotic dosing in 2 U.S. state hospitals. J Clin Psychiatry 2002, 63:998-1003.
19. Dickinson D., Harvey P.D. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull 2009, 35(2):403-414.
20. Elie D., Poirier M., Chianetta J., Durand M., Grégoire C., Grignon S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol 2010, 24(7):1037-1044. Epub ahead of print. 10.1177/0269881108100777.
21. Faries D., Ascher-Svanum H., Zhu B., Correll C., Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005, 5(1):26.
22. Faul F., Erfelder E., Lang A.-G., Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007, 39(2):175-191.
23. Faustman W.O., Hoff A.L. Effects of antipsychotic drugs on neuropsychological measures. Handbook of Experimental Pharmacology 1996, Vol. 120:445-471. Springer Verlag, Berlin.
24. Freudenreich O., Goff D.C. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002, 106:323-330.
25. Ganguly R., Kotzan J.A., Miller L.S., Kennedy K., Martin B.C. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004, 65(10):1377-1388.
26. Gold J.M. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 2004, 72:21-28.
27. Goldberg T.E., Green M.F. Neurocognitive functioning in patients with schizophrenia: An overview. Neuropsychopharmacology: The Fifth Generation of Progress 2002, 657-669. Lippincott Williams & Wilkins, Philadelphia. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
28. Goldberg T.E., Greenberg R.D., Griffin S.J. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993, 162:43-48.
29. Goldberg T.E., Goldman R.S., Burdickm K.E., Malhotram A.K., Lencz T., Patel R.C., et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: Is it a practice effect?. Arch Gen Psychiatry 2007, 64:1115-1122.
30. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
31. Green M.F. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. Am J Psychiatry 2007, 164(7):992-994.
32. ECDEU Assessment Manual for Psychopharmacology. Rockville 1976, US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, MD. W. Guy (Ed.).
33. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993, 34:702-712.
34. Hals P.A., Hall H., Dahl S.G. Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci 1988, 43(5):405-412.
35. Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001, 158:176-184.
36. Heaton R.K., Crowley T.J. Effects of psychiatric disorders and their somatic treatments on neuropsychological test results. Handbook of Clinical Neuropsychology 1981, 481-525. John Wiley & Sons, New York. S.D. Filskov, T.J. Boll (Eds.).
37. Honer W.G., Thornton A.E., Chen E.Y., Chan R.C., Wong J.O., Bergmann A., et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006, 354(5):472-482.
38. Hori H., Noguchi H., Hashimoto R., Nakabayashi T., Omori M., Takahashi S., et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006, 86(1-3):138-146.
39. Invega (paliperidone) [package insert]. Titusville, NJ:Janssen LP; April 2007.
40. Ito H., Koyama A., Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005, 187:243-247.
41. Jaffe A.B., Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003, 12:41-48.
42. Kane J.M., Aguglia E., Altamura A.C., Ayuso Gutierrez J.L., Brunello N., Fleischhacker W.W., et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998, 8:55-66.
43. Kawai N., Yamakawa Y., Baba A., Nemoto K., Tachikawa H., Hori T., et al. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(6):1009-1014.
44. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
45. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007, 64(6):633-647.
46. Knowles E.E., David A.S., Reichenberg A. Processing Speed Deficits in Schizophrenia: Reexamining the Evidence. Am J Psychiatry 2010, 167(7):828-835.
47. Kreyenbuhl J., Valenstein M., McCarthy J.F., Ganoczy D., Blow F.C. Long term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res 2006, 84(1):90-99.
48. Lal S., Thavundayil J.X., Nair N.P., Annable L., Ng Ying Kin N.M., Gabriel A., et al. Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. J Psychiatry Neurosci 2006, 31(4):271-279.
49. Lehman A.F., Steinwachs D.M. Translating research into practice: the Schizophrenia Patients Outcomes ResearchTeam (PORT) treatment recommendations. Schizophr Bull 1998, 24:1-10.
50. Lelliott P., Paton C., Harrington M., Konsolaki M., Ensky T.S., Ococha C. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatric Bull 2002, 26:411-414.
51. Levaux M.N., Potvin S., Sepehry A.A., Sablier J., Mendrek A., Stip E. Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. Eur Psychiatry 2007, 22(2):104-115.
52. Marder S.R., van Kammen D.P. Dopamine Receptor Antagonists (Typical Antipsychotics). Virginia A. Sadock (Author) Kaplan & Sadock's Comprehensive Textbook of Psychiatry 2000, 2360. Lippincott Williams & Wilkins, Philadelphia. B.J. Sadock, V.A. Sadock (Eds.).
53. McGuffin P., Farmer A., Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991, 48(8):764-770.
54. Medalia A., Gold J.M., Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 1988, 3:249-271.
55. Minzenberg M.J., Poole J.H., Benton C., Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004, 161(1):116-124.
56. Mishara A.L., Goldberg T.E. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004, 55:1013-1022.
57. Mortimer A.M. Cognitive function in schizophrenia-do neuroleptics make a difference?. Pharmacol Biochem Behav 1997, 56:789-795.
58. Pantelis C., Barnes T.R., Nelson H.E., Tanner S., Weatherley L., Owen A.M., et al. Frontal-striatal cognitive deficits in patients with chronic schizophrenia. Brain 1997, 120(Pt 10):1823-1843.
59. Peretti C.S., Danion J.M., Kauffmann-Muller F., Grangé D., Patat A., Rosenzweig P. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers. Psychopharmacology (Berl) 1997, 131(4):329-338.
60. Perlick D., Stastny P., Katz I., Mayer M., Mattis S. Memory deficits and anticholinergic levels in chronic schizophrenia. Am J Psychiatry 1986, 143:230-232.
61. Procyshyn R.M., Kennedy N.B., Tse G., Thompson B. A antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001, 46(4):334-339.
62. Sim K., Su A., Leong J.Y., Yip K., Chong M.Y., Fujii S., et al. High dose antipsychotic use in schizophrenia: findings of the REAP (Research on East Asia Psychotropic Prescriptions) study. Pharmacopsychiatry 2004, 37:175-179.
63. Sim K., Su H.C., Fujii S., Yang S.Y., Chong M.Y., Ungvari G., et al. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol 2009, 67(1):110-117.
64. Spohn H.E., Strauss M.E. Relation of neuroleptic and anticholinergic medication to cognitive functions of schizophrenia. J Abnorm Psychol 1989, 98:367-380.
65. Stahl S.M., Grady M.M. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004, 11(3):313-327.
66. Sunderland T., Tariot P.N., Newhouse P.A. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res 1988, 472:371-389.
67. Tapp A., Wood A.E., Secrest L., Erdmann J., Cubberley L., Kilzieh N. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003, 54(1):55-59.
68. Tiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374:620-627.
69. Tune L.E., Strauss M.E., Lew M.F., Breitlinger E., Coyle J.T. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982, 139:1460-1462.
70. Tyson P.J., Laws K.R., Roberts K.H., Mortimer A.M. Stability of set-shifting and planning abilities in patients with schizophrenia. Psychiatry Res 2004, 129(3):229-239.
71. Tyson P.J., Laws K.R., Roberts K.H., Mortimer A.M. A longitudinal analysis of memory in patients with schizophrenia. Clin Exp Neuropsychol 2005, 27(6):718-734.
72. Vinogradov S., Fisher M., Warm H., Holland C., Kirshner M.A., Pollock B.G. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 2009, 166(9):1055-1062.
73. Wechsler D. Wechsler Adult Intelligence Scale-III (WAIS-III) 1997, The Psychological Corporation, New York.
74. Weinmann S., Read J., Aderhold V. Influence of antipsychotics on mortality in schizophrenia: Systematic review. Schizophr Res 2009, 113:1-11.
75. WHO WHO Collaborating Centre for Drug Statistics Methodology: ATC classification index with DDDs 2008 2008, World Health Organization, Oslo, Norway.
76. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003, 64:663-667.
77. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005, 8:457-472.
78. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007, 89:211-224.
79. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry. 2010; 23(2):103-11.